Shopping Cart
- Remove All
- Your shopping cart is currently empty
Vanucizumab, a pioneering bispecific IgG1-like monoclonal antibody, concurrently inhibits the interaction of VEGF-A and angiopoietin-2 (Ang-2) with their respective receptors, exerting antiangiogenic and anticancer properties [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $290 | 2-4 weeks | |
5 mg | $755 | 2-4 weeks | |
10 mg | $1,200 | 2-4 weeks |
Description | Vanucizumab, a pioneering bispecific IgG1-like monoclonal antibody, concurrently inhibits the interaction of VEGF-A and angiopoietin-2 (Ang-2) with their respective receptors, exerting antiangiogenic and anticancer properties [1]. |
Cas No. | 1448221-05-3 |
Storage | store at -80°C | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.